Is levonorgestrel intra-uterine system in menorrhagia: effective and acceptable? A retrospective study
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20260551Keywords:
Acceptability, Continuation rate, Dysmenorrhea, Heavy menstrual bleeding, Levonorgestrel IUSAbstract
Background: This study aimed to evaluate the effectiveness, acceptability, satisfaction and continuation rates of the levonorgestrel intrauterine system (LNG-IUS) in women with heavy menstrual bleeding (HMB) and to assess associated adverse effects.
Methods: This retrospective study was conducted in the Department of Obstetrics and Gynaecology, Vijaya Hospital, Chennai. Fifty-five women who underwent LNG-IUS insertion for HMB between January 2023 and January 2025 were identified from outpatient records. Demographic details, co-morbidities, menstrual patterns, ultrasound findings, and histopathology reports were reviewed. Follow-up assessments at 3 and 6 months included evaluation of menstrual blood loss, dysmenorrhea, side effects, and satisfaction scores. Continuation and acceptability rates were documented. Patient satisfaction was measured on a 1-5 scale.
Results: The mean age of participants was 42.3 years, and 78% were overweight or obese. A significant reduction in menstrual blood loss was observed, with 90% showing improvement by 6 months. Amenorrhea occurred in 44%, normal bleeding in 26%, and spotting in 20% of women. Dysmenorrhea decreased from 64% at beginning to 4% at 6 months. The continuation rate was 90% and the overall satisfaction score was 74.5%. The LNG-IUS expulsion rate was 10%. The most common adverse effects were spotting (25%) and simple ovarian cysts (20%).
Conclusions: LNG-IUS is an effective, acceptable, and minimally invasive therapeutic option for HMB, offering substantial improvement in symptoms, high continuation rates, and favourable tolerability. It serves as a safe and cost-effective alternative to conventional medical and surgical treatments.
References
Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3-13. DOI: https://doi.org/10.1016/j.ijgo.2010.11.011
Wright RC. Hysterectomy: past, present, and future. Obstet Gynecol. 1969;33(4):560-3.
Goñi AZ, Lacruz RL, Paricio JJ, Hernández Rivas FJ. The levonorgestrel intrauterine system as an alternative to hysterectomy for the treatment of idiopathic menorrhagia. Gynecol Endocrinol. 2009;25(9):581-6. DOI: https://doi.org/10.1080/09513590902972034
Hubacher D, Grimes DA. Non- contraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv. 2002;57(2):120-8. DOI: https://doi.org/10.1097/00006254-200202000-00024
Bafna BA, Bafna AN. Levonorgestrel intrauterine system in menorrhagia an effective and acceptable alternative. Int J Reprod Contracept Obstet Gynecol. 2021;10(4):1665-70. DOI: https://doi.org/10.18203/2320-1770.ijrcog20211155
Taru G, Nupur G, Sangeeta G, Pushpa B, Jyoti J, Sushma K. Levonorgestrel intrauterine system (LNG IUS) in menorrhagia: a follow-up study. Open J Obstet Gynecol. 2014;4:190-6. DOI: https://doi.org/10.4236/ojog.2014.44032
Utman N, Faheem F. Levonorgestrel intra uterine system (LNG IUS) in menorrhagia: a three years follow-up study. J Postgrad Med Inst. 2011;26(1).
Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(3):625-32. DOI: https://doi.org/10.1097/AOG.0b013e3181ec622b
Chattopdhyay B, Nigam A, Goswami S, Chakravarty PS. Clinical outcome of levonorgestrel intra-uterine system in idiopathic menorrhagia. Eur Rev Med Pharmacol Sci. 2011;15(7):764-8.
Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M. A Canadian, multicentre study comparing the efficacy of a levonorgestrel releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can. 2009;31(4):340-7. DOI: https://doi.org/10.1016/S1701-2163(16)34151-2
Reid PC, Virtanen-Kari S. Randomized comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG. 2005;112(8):1121-5. DOI: https://doi.org/10.1111/j.1471-0528.2005.00642.x
Vilos GA, Tureanu V, Garcia M, Abu-Rafea B. The levonorgestrel intrauterine system is an effective treatment in women with abnormal uterine bleeding and anticoagulant therapy. J Minim Invas Gynecol. 2009;16(4):480-4. DOI: https://doi.org/10.1016/j.jmig.2009.04.018
Rodriguez MI, Darney PD. Non-contraceptive applications of the levonorgestrel intrauterine system. Int J Wom Health. 2010;2:63-8. DOI: https://doi.org/10.2147/IJWH.S6344
Downloads
Published
How to Cite
Issue
Section
